← Filings of ASST

Tables in the 10-Q of Strive, Inc.

24 tables with numbers, filed May 14, 2026. Each one downloads as a CSV for Excel or Google Sheets, with the filing's address in the last row. Only the layout is tidied (a "$" or ")" in a cell of its own is joined to its number); no value is changed. Open the filing on sec.gov ↗

		Page
PART I.	FINANCIAL INFORMATION	1
Item 1.	Consolidated Financial Statements	1
	Consolidated Statements of Financial Condition as of March 31, 2026 (unaudited) and December 31, 2025 (audited)	1
	Consolidated Statements of Operations (unaudited) for the Three Months Ended March 31, 2026 (Successor) and 2025 (Predecessor)	2
	Consolidated Statements of Changes in Stockholders' Equity (unaudited) for the Three Months Ended March 31, 2026 (Successor) and 2025 (Predecessor)	3
	Consolidated Statements of Cash Flows (unaudited) for the Three Months Ended March 31, 2026 (Successor) and 2025 (Predecessor)	4
	Notes to Consolidated Financial Statements (unaudited)	6

	March 31, 2026	December 31, 2025
	(unaudited)	(audited)
Assets:
Current assets:
Cash and cash equivalents	$95,092		$67,499
Investments in preferred equity, at fair value	50,510		—
Prepaid expenses	2,590		2,708
Other current assets	2,787		1,569

	Successor	Predecessor
	Three Months Ended March 31, 2026	Three Months Ended March 31, 2025
Revenues:
Investment advisory fees	$1,347		$1,416
Medical device revenues	1,370		—
Other revenue	43		7
Total revenues	2,760		1,423
Operating expenses:

	Predecessor
	Mezzanine Equity		Stockholders' Equity
	Successor Perpetual		Predecessor	Predecessor Class A		Predecessor Class B		Successor Class A	Successor Class B	Additional	Retained Earnings/		Total
	Preferred Stock		Preferred Stock	Common Stock		Common Stock		Common Stock	Common Stock	Paid-in	(Accumulated		Stockholders'
	Shares	Amount		Shares		Amount		Shares	Par Value	Shares	Par Value		Shares		Par Value	Shares	Par Value	Capital		Deficit)		Equity
Balance at December 31, 2024	—	$—			1,158,802		$72,488		2,000,000	$—		400,970		$—		—	$—		—		$—		$—	$(49,146)	$23,342
Net loss	—	—			—		—		—	—		—		—		—	—		—		—		—	(3,749)	(3,749)
Balance at March 31, 2025	—	$—			1,158,802		$72,488		2,000,000	$—		400,970		$—		—	$—		—		$—		$—	$(52,895)	$19,593

Release of bitcoin held as collateral upon extinguishment of Coinbase Loan	37,971	—
Exchange of preferred stock for extinguishment of long-term notes payable, at fair value	90,108	—
Class A common stock issued as part of business combination	311,183	—
Assets and liabilities resulting from business combination:
Prepaid expenses	599	—
Other current assets	1,831	—
Digital assets, at fair value	444,029	—
Receivable for bitcoin collateral	37,971	—

	Three Months Ended March 31, 2026
Balance, beginning of period	$668,486
Acquisitions	521,311
Release of bitcoin held as collateral upon extinguishment of Coinbase loan	35,377
Sales	—
Aggregate cost basis	1,225,174
Change in fair value	(295,778)
Balance, end of period	$929,396

	March 31, 2026	December 31, 2025
Approximate number of bitcoin held	13,628	7,627
Weighted average acquisition cost	104,174	113,153
Fair value per bitcoin	68,198		87,650

Other current assets	1,831
Digital assets	444,029
Receivable for bitcoin collateral	37,971
Intangible assets	14,650
Property and equipment	175
Other non-current assets	1
Accounts payable and other liabilities	(13,029)
Compensation and benefits payable	(2,358)

		March 31, 2026	December 31, 2025
	Level	Fair Value	Fair Value
Assets:
Investments in preferred equity, at fair value	Level 1	$50,510		$—
Digital assets, at fair value	Level 1	929,396		668,486
Liabilities:
Long-term notes payable, at fair value	Level 1	$9,701		$—

	Three Months Ended March 31, 2026
	PIPE Traditional Warrants	PIPE Pre-Funded Warrants
PIPE warrants outstanding, beginning of period	531,888,702		1,072,289
Issued	—		—
Exercised	—		(1,072,289)
Expired	—		—
PIPE warrants outstanding, end of period	531,888,702		—
(1) Each warrant gives the holder the right to purchase 1/20th of a share of Class A common stock.

Income tax benefit/(expense)	—	—	—	—
Net loss	$(2,001)	$(5,905)	$(258,000)	$(265,906)

	March 31, 2026	December 31, 2025
Asset Management	$1,284		$1,279
Medical Device	17,632		—
Corporate & Other	1,081,353		744,248
Total	$1,100,269		$745,527

Other revenue	43	7	36	514.3%
Total revenues	2,760	1,423	1,337	94.0%
Operating expenses:
Fund management and administration	1,424	1,411	13	0.9%
Employee compensation and benefits	13,053	2,066	10,987	531.8%
General and administrative expense	5,938	1,906	4,032	211.5%
Marketing and advertising	116	61	55	90.2%
Depreciation and amortization	90	52	38	73.1%

Exhibit Number	Description
3.1	Certificate of Change of Strive, Inc., as filed with the Nevada Secretary of State on February 3, 2026 and effective on February 6, 2026 (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on February 3, 2026).
3.2*	Amended and Restated Certificate of Designation relating to the Variable Rate Series A Perpetual Preferred Stock
4.1	Indenture, dated as of January 28, 2025, between Semler Scientific, Inc. and U.S Bank Trust Company, National Association, as Trustee (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on January 16, 2026).
4.2	Supplemental Indenture, dated as of January 16, 2026, by and among Semler Scientific, Inc., Strive, Inc., as guarantor and U.S Bank Trust Company, National Association, as Trustee (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed on January 16, 2026).
4.3	Form of Global Note, representing Semler Scientific, Inc.’s 4.25% Convertible Senior Notes due 2030 (included in Exhibit 4.3).
31.1*	Certification pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Principal Executive Officer.
31.2*	Certification pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Principal Financial Officer.

	Three Months Ended March 31, 2026 (Successor)
	Asset Management	Medical Device		Corporate & Other	Total Consolidated
Revenues:
Investment advisory fees	$1,347		$—		$—	$1,347
Medical device revenues	—		1,370		—	1,370
Other revenue	—		—		43	43
Total revenues	1,347		1,370		43	2,760
Operating expenses:

	Three Months Ended March 31, 2025 (Predecessor)
	Asset Management	Medical Device		Corporate & Other	Total Consolidated
Revenues:
Investment advisory fees	$1,416		$—		$—	$1,416
Medical device revenues	—		—		—	—
Other revenue	7		—		—	7
Total revenues	1,423		—		—	1,423
Operating expenses:

Tables in the 10-Q of Strive, Inc.

Table 1 after “TABLE OF CONTENTS”

Table 2 after “(in thousands, except share and per share data)”

Table 3 after “(unaudited)”

Table 4 after “(unaudited)”

Table 5 after “(unaudited)”

Table 6 after “4”

Table 7 after “The following table provides a summary of the changes in the Company's digital assets, at fair value for the three months ended March 31, 20”

Table 8 after “The Company's investments in digital assets, at fair value are summarized below. The Company did not hold any investments in digital assets ”

Table 9 after “8”

Table 10 after “A summary of the changes of the Company's investments in preferred equity, at fair value are summarized below (in thousands):”

Table 11 after “The table below summarizes the Company's investment advisory fees, medical device revenues, and other revenue (in thousands):”

Table 12 after “The tables below provides a summary of the Company's financial assets and liabilities carried at fair value on a recurring basis, including ”

Table 13 after “The table below summarizes activity related to the Company's PIPE Traditional Warrants and PIPE Pre-Funded Warrants for the three months end”

Table 14 after “Basic and diluted earnings (loss) per common share are calculated as follows (in thousands, except for share and per share data):”

Table 15 after “The following summarizes the information reviewed by the CODM to evaluate the net income (loss) of the Company's Asset Management, Medical D”

Table 16 after “18”

Table 17 after “18”

Table 18 after “The total assets of the Company's operating segments are summarized as follows (in thousands):”

Table 19 after “The following table presents information regarding the consolidated results of operations for the three months ended March 31, 2026 (Success”

Table 20 after “23”

Table 21 after “The following table summarizes Strive's available liquidity (in thousands):”

Table 22 after “The following table summarizes Strive's cash flow activities (in thousands):”

Table 23 after “Non-GAAP adjusted net income (loss), non-GAAP adjusted net income (loss) attributable to common stockholders, and the related non-GAAP adjus”

Table 24 after “INDEX TO EXHIBITS”